hormoneInjectableNot FDA-approvedResearch chemicalNot an FDA-approved drug; sold online as a research chemical despite marketing that calls it an oral fat-loss or endurance productHuman oral absorption has never been studied; all pharmacology to date is rodent injection or cultured human cells
SR-9009Benefits, Dosage & Interactions
Also known as: Stenabolic
SR-9009, also known by its research code Stenabolic, is a synthetic compound that has been extensively studied for its role as a Rev-ErbA alpha (Rev-ErbAα) agonist. Rev-ErbAα is a nuclear receptor involved in regulating circadian rhythms and metabolism. Research on SR-9009 focuses on endurance.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
Evidence: Preclinical — Animal and in-vitro studies only, no published human RCTs.
Evidence strengthPreclinical · 1/4
PreclinicalStrong human evidence
Animal and in-vitro studies only, no published human RCTs.
Plasma half-life
Not established
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- Mouse studies dosed 100 mg/kg intraperitoneally twice daily; there is no human dose reported anywhere in the literature[1]
- Route studied
- Intraperitoneal injection in the original circadian-behavior study, reflecting poor oral bioavailability in rodents[1]
- Frequency
- Twice-daily injections in the cited mouse studies[1]
Reported for SR-9009 in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the SR-9009 entry is written from. Each number matches an inline marker above.
- [1]Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonistsSolt LA, Wang Y, Banerjee S, Hughes T, Kojetin DJ, Lundasen T, Shin Y, Liu J, Cameron MD, Noel R, Yoo SH, Takahashi JS, Butler AA, Kamenecka TM, Burris TP · Nature · 2012 · Peer-reviewed · PMID 22460951
- [2]SR9009 induces a REV-ERB dependent anti-small-cell lung cancer effect through inhibition of autophagySulli G, Rommel A, Wang X, Kolar MJ, Puca F, Saghatelian A, Plikus MV, Verma IM, Panda S · Nature · 2020 · Peer-reviewed · PMID 32292508
- [3]SR9009 improves heart function after pressure overload independent of cardiac REV-ERBSundaram J, et al. · iScience · 2022 · Peer-reviewed · PMID 35911512
How to track SR-9009 doses
SR-9009 is tracked as a protocol rather than a single reminder: a vial with a concentration, a schedule that may be titrated or cycled, and a rotation of injection sites. Here is the record that keeps all three consistent.
- 1
Record the vial and concentration
Log the vial strength and the volume of bacteriostatic water you added so SR-9009 is stored as a concentration rather than a guess. DoseRoutine converts that into mg per syringe unit and counts the doses left in the vial as you log.
- 2
Set the schedule, not just a reminder
Enter the dose in mg and the frequency. Cycled protocols get a start and end date so the history stays accurate when SR-9009 comes out of the routine.
- 3
Rotate and log the injection site
Pick the site at the moment you log the dose. The site map shows what you used last and how recently, which is the part that drifts fastest when two compounds run on different frequencies.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
Review SR-9009 alongside your logged metrics and any relevant blood work every few weeks before changing the dose, so the change is a response to data rather than to a good or bad day.
What to log each time
- Dose in mg and the syringe units it worked out to
- Vial: reconstitution date, concentration, doses remaining
- Injection site and time
- Any side effects in the 24 h after the dose
References & Evidence
Sources on this page that document SR-9009 dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is SR-9009 studied for?
What is SR-9009?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
SR-9009, also known by its research code Stenabolic, is a synthetic compound that has been extensively studied for its role as a Rev-ErbA alpha (Rev-ErbAα) agonist. Rev-ErbAα is a nuclear receptor involved in regulating circadian rhythms and metabolism. While not a Selective Androgen Receptor Modulator (SARM), SR-9009 is often discussed in contexts similar to SARMs due to its reported effects on body composition and endurance in preclinical studies. It was developed at The Scripps Research Institute and has primarily been investigated for its potential to influence energy balance, glucose metabolism, and lipid profiles.
Preclinical research, mainly conducted in mouse models, indicates that SR-9009 can impact various metabolic processes. These include increasing mitochondrial content and activity in skeletal muscle, which may contribute to improved exercise capacity, and influencing fat and glucose metabolism. The compound is not approved for human use by regulatory bodies like the FDA, and its status is strictly limited to research. Information regarding its efficacy and safety in humans is derived from early-stage research and anecdotal reports, rather than robust clinical trials. (Source: PubChem, DrugBank)
What does the research say about SR-9009?
Tap a section to expand.
SR-9009 functions as a synthetic ligand for Rev-ErbAα, a nuclear receptor that plays a critical role in regulating the body's internal clock (circadian rhythm) and metabolism. When SR-9009 binds to and activates Rev-ErbAα, it leads to several downstream effects. Key among these is the modulation of gene expression related to metabolic processes. Rev-ErbAα acts as a transcriptional repressor, meaning its activation by SR-9009 generally leads to a decrease in the expression of genes it controls.
Specifically, SR-9009's activation of Rev-ErbAα is understood to:
* **Repress genes involved in lipid synthesis and storage:** This contributes to observations of reduced fat mass in animal studies.
* **Increase mitochondrial biogenesis:** Encourages the formation of new mitochondria, the 'powerhouses' of cells, particularly in skeletal muscle. This enhanced mitochondrial density is thought to improve oxidative capacity and endurance.
* **Modulate glucose metabolism:** Influence the body's handling of glucose, potentially improving insulin sensitivity.
* **Affect circadian clock genes:** As a Rev-ErbAα agonist, it directly impacts the core molecular clock, which in turn influences daily rhythms of metabolism, energy expenditure, and activity.
The overall result in preclinical models is a shift towards a more catabolic state where the body utilizes stored energy more efficiently, mimicking some effects of exercise. (Source: PubChem, DrugBank)
Source for this section: Sources for How does SR-9009 work?: Jumps to this entry in the sources and references list at the end of the page.
Preclinical studies, primarily in rodent models, have explored several potential benefits of SR-9009 related to metabolism and physical performance. It is important to note that these findings have not been replicated or confirmed in human clinical trials.
* **Improved Exercise Endurance:** Research in mice has shown that SR-9009 can increase running distance and time to exhaustion. This is thought to be mediated by increased mitochondrial content and enhanced oxidative metabolism in skeletal muscle, leading to more efficient energy production during physical activity. (Source: published preclinical research)
* **Reduced Fat Mass:** Studies suggest that SR-9009 can reduce fat mass by promoting the breakdown of lipids and inhibiting their synthesis and storage. This effect has been observed without significant changes in food intake in some animal models. (Source: published preclinical research)
* **Enhanced Glucose Metabolism:** Some preclinical data indicate that SR-9009 may improve insulin sensitivity and glucose tolerance. This could be beneficial for conditions characterized by impaired glucose utilization. (Source: published preclinical research)
* **Modulation of Cholesterol Levels:** In animal models, SR-9009 has shown potential to reduce plasma triglyceride and total cholesterol levels. (Source: published preclinical research)
These potential benefits are speculative in humans due to the lack of clinical data. It is crucial to understand that results from animal studies do not always translate to humans. (Source: NIH ODS, DrugBank)
The evidence for SR-9009's effects comes almost exclusively from preclinical animal studies. The initial research, largely from the lab of Professor Thomas Burris, demonstrated that SR-9009 acts as a potent synthetic Rev-ErbAα agonist.
One landmark study in mice published in *Nature Medicine* showcased that SR-9009 increased endurance exercise capacity by boosting mitochondrial biogenesis in skeletal muscle and enhancing oxygen consumption. Mice treated with SR-9009 were able to run significantly longer distances and for more extended periods than control groups, even without additional exercise. This study also highlighted reductions in fat mass and improvements in cholesterol and glucose metabolism in obese mice. (Source: published preclinical research, e.g., Nature Medicine)
Further animal research has supported these initial findings, suggesting SR-9009's potential in addressing metabolic disorders. For example, studies have indicated its ability to protect against diet-induced obesity and improve various markers of metabolic syndrome in rodent models. The mechanistic understanding of SR-9009's action through Rev-ErbAα has been well-established in *in vitro* and *in vivo* animal models. (Source: PubChem, DrugBank)
However, there is a distinct lack of human clinical trials evaluating the safety, efficacy, and pharmacokinetics of SR-9009. Therefore, any extrapolation of these preclinical benefits to humans is speculative and unsupported by human-specific evidence. Regulatory bodies have not approved SR-9009 for human use, and its human application remains primarily within the realm of unapproved research compounds. (Source: NIH ODS, DrugBank)
Due to the absence of human clinical trials, the known side effects of SR-9009 are largely speculative and based on theoretical considerations or anecdotal reports, which are not scientifically validated. Potential side effects could theoretically arise from its interference with circadian rhythms and widespread metabolic effects.
Some speculative concerns, based on its mechanism of action as a Rev-ErbAα agonist and animal studies, include:
* **Disruption of Circadian Rhythm:** As Rev-ErbAα plays a central role in the body's clock, manipulating it could potentially disrupt sleep patterns, hormone secretion, and other daily physiological processes.
* **Metabolic Disregulation Unintendedly:** While targeting specific metabolic benefits, broad modulation of such fundamental pathways could lead to un foreseen metabolic consequences.
* **Impact on Liver Function:** Given that the liver is a major metabolic organ and Rev-ErbAα is expressed there, there is a theoretical concern for liver stress or alteration in liver enzyme levels, though this is not confirmed in humans.
* **Lack of Long-Term Safety Data:** The absence of human trials means there is no data on long-term safety or potential chronic effects.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
SR-9009 is an investigational compound not approved for human consumption by regulatory agencies such as the FDA. Its safety and efficacy in humans have not been established through clinical trials. Users should be aware of the following significant warnings:
* **Unapproved for Human Use:** SR-9009 is classified as a research chemical. Using it for self-medication or performance enhancement is illegal in many jurisdictions and carries significant health risks due to the lack of regulatory oversight and human safety data.
* **Unknown Human Pharmacokinetics:** How SR-9009 is absorbed, distributed, metabolized, and excreted in the human body is not fully understood. This makes accurate dosing and prediction of effects or interactions extremely difficult and potentially dangerous.
* **Potential for Undisclosed Contaminants:** Because SR-9009 is purchased through unregulated channels, there is a high risk of receiving products that are mislabeled, impure, or contaminated with other potentially harmful substances. The actual content may not match what is advertised.
* **No Long-Term Safety Data:** The long-term health consequences of SR-9009 use in humans are completely unknown. Any benefits observed in animal models may not translate to humans, and irreversible harm could occur.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Given that SR-9009 is an investigational compound with no established human safety profile, specific contraindications have not been determined through clinical research. However, based on its proposed mechanism of action and general medical principles, it would be prudent to assume that SR-9009 would be contraindicated in a broad range of individuals and conditions:
* **Pregnancy and Breastfeeding:** Due to unknown risks to fetal development and infant health.
* **Children and Adolescents:** Due to potential interference with growth and development.
* **Individuals with Pre-existing Medical Conditions:** Especially those related to metabolic disorders, cardiovascular disease, liver, or kidney dysfunction, as SR-9009's effects on these systems are largely uncharacterized in humans and could exacerbate existing conditions.
* **Individuals Taking Prescription Medications:** Due to the high potential for unknown drug-drug interactions.
* **Individuals Undergoing Surgery:** Due to potential effects on metabolism and recovery processes.
Without human clinical data, any use of SR-9009 is entirely experimental and carries inherent, undefined risks. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
There is no scientific data regarding specific drug-drug or supplement-supplement interactions for SR-9009 due to the lack of human clinical trials. As an experimental compound that significantly impacts metabolic pathways and circadian rhythms, it is theoretically possible that SR-9009 could interact with a wide range of medications and supplements. Without evidence, any combination should be considered potentially risky.
Based on its known mechanism in animal models, particular caution would be advised with:
* **Medications affecting metabolism:** Such as antidiabetic drugs (e.g., insulin, metformin) or cholesterol-lowering agents (e.g., statins), as SR-9009 also modulates glucose and lipid metabolism, potentially leading to additive or antagonistic effects.
* **Medications influencing circadian rhythm:** Including certain psychiatric medications or sleep aids, due to SR-9009's role as a Rev-ErbAα agonist.
* **Liver-metabolized drugs:** Given the role of the liver in metabolism and the unknown human pharmacokinetics of SR-9009, there's a theoretical risk of interactions with drugs processed by hepatic enzymes.
* **Stimulants or other performance-enhancing compounds:** Combining SR-9009 with other substances intended for performance enhancement could amplify side effects or lead to unforeseen adverse outcomes.
Until robust human studies are conducted, the safest approach is to assume that SR-9009 could interact negatively with virtually any other substance. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
For research purposes, SR-9009 has a relatively short half-life, estimated at approximately 4 hours in preclinical models, though human pharmacokinetics are unknown. Given the lack of human data and regulatory approval, there are no established guidelines for timing or administration in humans. Any discussion of timing is purely theoretical and derived from animal research or anecdotal reports.
In animal studies, SR-9009 has been administered at various frequencies to observe its metabolic effects. The short half-life suggests that, if it were to be effective in humans, consistent administration or multiple daily administrations might be considered to maintain its presence in the body. However, this remains speculative and not advisable without clinical validation.
It can be taken with or without food, as preclinical research has not indicated a strong interaction with food intake concerning its bioavailability.
Dose is user-directed and must be set by a licensed clinician. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Source for this section: Sources for When should you take SR-9009?: Jumps to this entry in the sources and references list at the end of the page.
What interacts with SR-9009?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any peptide + hormone | Note | Category ruleConfidence: theoretical | Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.Source pending | Track bloodwork with a provider; don't assume combinations are neutral. |
Frequently asked questions about SR-9009
* A: No, SR-9009 is not a Selective Androgen Receptor Modulator (SARM). It is a Rev-ErbAα agonist, affecting metabolic pathways and circadian rhythms, distinct from SARMs which target androgen receptors.
* A: No, SR-9009 has not been approved for human use by any regulatory body, such as the FDA. It remains an investigational chemical for research purposes only.
* A: In preclinical animal studies, SR-9009 has shown potential to improve exercise endurance, reduce fat mass, enhance glucose metabolism, and modulate cholesterol levels. These findings are not confirmed in humans.
* A: Due to the lack of human clinical trials, the full spectrum of side effects in humans is unknown. Theoretical concerns include circadian rhythm disruption and unforeseen metabolic deregulation.
* A: SR-9009 was developed at The Scripps Research Institute as a synthetic compound for research into metabolic and circadian biology.
SR-9009 is a hormone, and interactions are possible with prescriptions, hormones, peptides and other supplements in the same routine. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers SR-9009 with no sign-up.
Ranges reported in the literature are not recommendations; use the dose your clinician or the product label gives you.
Combining a hormone like SR-9009 with TRT is usually a question of labs rather than a blanket yes or no: the ester, injection interval and any aromatase inhibitor all change the answer. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Each peptide class carries its own profile against SR-9009: a healing peptide raises different questions than a GLP-1 agonist or a growth-hormone secretagogue. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
Published frequency for SR-9009 varies by protocol and formulation, so the label or prescription is what sets it. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
The effect of a missed dose of SR-9009 depends on the protocol and formulation you are on. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For SR-9009 the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Which studies looked at SR-9009?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.In vitro metabolism of the REV-ERB agonist SR-9009 and subsequent detection of metabolites in associated routine equine plasma and urine doping control samples(opens PubMed in a new tab)Drug Test Anal · 2022 · PMID 34224639 · https://pubmed.ncbi.nlm.nih.gov/34224639/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 57394020(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/57394020
Verify at
Publisher search links for SR-9009. These are places to check the information — they are not citations, so they are not numbered.
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- NIH Office of Dietary Supplements(publisher search, opens in a new tab)National Institutes of Health · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- DailyMed labeling archive(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on SR-9009?
Plain-text summary, safe to quote verbatim:
SR-9009, also known by its research code Stenabolic, is a synthetic compound that has been extensively studied for its role as a Rev-ErbA alpha (Rev-ErbAα) agonist. Rev-ErbAα is a nuclear receptor involved in regulating circadian rhythms and metabolism. Research on SR-9009 focuses on endurance.
Source: DoseRoutine — https://doseroutine.com/library/sr-9009
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). SR-9009 — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/sr-9009
What compounds are similar to SR-9009?
Others in the hormone category or studied for the same goals.
Which goals is SR-9009 used for?
Other compounds studied for the same benefits as SR-9009.
Continue exploring
See every compound DoseRoutine catalogs for these goals.